'Not-Approvable' Letter Fits Trend For Optical Cancer Detectors, Guided Therapeutics Says
This article was originally published in The Gray Sheet
Executive Summary
The company's response to an FDA not-approvable letter for its LuViva cervical cancer scanner will be guided by the experiences of other light-based cancer detector developers that encountered the same initial setback. The firm's likely next step: petitioning FDA for an advisory panel meeting.
You may also be interested in...
News Briefs: Dx Bill Reintroduced; FDA Questions Guided Therapeutics’ LuViva; Study Milestones
Rep. Leonard Lance reintroduced a bill in the House to address flaws in Medicare’s reimbursement system for diagnostics. Guided Therapeutics receives more questions from FDA on the PMA for its LuViva cervical scan. Study news from InSightec, Direct Flow Medical and PLC Systems. More news.
Regulatory News In Brief
News on FDA workforce troubles, feedback on CDRH’s eCopy policy and more.
NCI-Funded Device Start-Ups Offer Game-Changing Technologies
At the NCI SBIR 2012 Investor Forum, a select group of SBIR grant-funded emerging cancer device companies presented promising next-generation technologies poised to dramatically impact survival from a variety of cancers, including deadly lung, liver, and esophageal malignancies.